Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001982476 XXXXXXXX LIVE 1 Common Stock, par value $0.00001 per share 09/11/2026 true 0001661053 29415J205 enVVeno Medical Corp 70 Doppler Irvine CA 92618 Ross. D. Carmel, Esq. (212) 930-9700 1185 Avenue of the Americas 31st Floor New York NY 10036 0001982476 N Braeden Lichti PF N Z4 0.00 0.00 0.00 000.00 0.00 N 0.00 IN On September 11, 2026, Braeden Lichti sold all of his previously owned shares of enVVeno Medical Corp ("Issuer")'s common stock, par value $0.00001 per share ("Common Stock") and no longer owns any shares of Common Stock of the Issuer. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for Mr. Lichti. 0002099270 N Northstrive Fund II LP WC N DE 0.00 0.00 0.00 0.00 0.00 N 0.00 IN From September 11, 2026 to September 14, 2026, Northstrive Fund II LP sold all of its previously owned shares of the Common Stock, and no longer owns any shares of Common Stock. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for Northstrive Fund II LP. Common Stock, par value $0.00001 per share enVVeno Medical Corp 70 Doppler Irvine CA 92618 This Schedule 13D is filed jointly by Northstrive Fund II LP ("Northstrive Fund") and Braeden Lichti (together with Northstrive Fund, the "Reporting Persons"). The shares of Common Stock are held by Northstrive Fund and Mr. Braeden Lichti. Braeden Lichti is, as of the date of this Schedule 13D/A filing, the Manager of Northstrive Fund. The address of each of Northstrive Fund and Mr. Lichti is 120 Newport Center Drive, Newport Beach, CA 92660. Northstrive Fund is principally engaged in the business of investments into private and public securities. Mr. Lichti is principally engaged as the Chief Executive Officer of Northstrive Companies Inc., a California based management, advisory and investment company. None of the Reporting Persons have, during the last five years, been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws. None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws. Northstrive Fund is a Delaware limited partnership. Mr. Lichti is a citizen of Canada. The information set forth in Item 4 is incorporated by reference herein. Mr. Lichti previously used personal funds to purchase his previously owned Common Stock. Northstrive Fund previously used working capital as the source of funds for the purchase of its previously owned Common Stock. On September 11, 2026, Braeden Lichti sold all of his previously owned shares of the Issuer's Common Stock and no longer owns any shares of Common Stock. From September 11, 2026 to September 14, 2026, NorthStrive Fund II LP sold all of its previously owned shares of the Common Stock, and no longer owns any shares of Common Stock. Previously, the Reporting Persons herein filed a Schedule 13D with the U.S. Securities and Exchange Commission on February 20, 2026 ("Schedule 13D"), which reported the number of shares held by each reporting person as of February 20, 2026. This Schedule 13D/A filing is the final amendment to the Schedule 13D and constitutes an exit filing for Braeden Lichti and NorthStrive Fund II LP. For Northstrive Fund II LP, none as of February 11, 2026. For Braeden Lichti, none as of February 14, 2026. Sole power to vote or to direct the vote: Northstrive Fund II LP: 0 shares Braeden Lichti: 13,0 shares Shared power to vote or to direct the vote: Northstrive Fund II LP: 0 shares Braeden Lichti: 0 shares Sole power to dispose or to direct the disposition of: Northstrive Fund II LP: 0 shares Braeden Lichti: 0 shares Shared power to dispose or to direct the disposition: Northstrive Fund II LP: 0 shares Braeden Lichti: 0 shares The information set forth in Item 3 above is incorporated herein by reference. Not applicable. Not applicable. The information in Items 3 and 4 are incorporated herein by reference. Braeden Lichti /s/ Braeden Lichti Braeden Lichti, individually 09/15/2026 Northstrive Fund II LP /s/ Braeden Lichti Braeden Lichti/Manager 09/15/2026